Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gynuity Health Projects
With
Government Medical College, Nagpur
Daga Memorial Women's Hospital, Nagpur, India
University of British Columbia
Bill and Melinda Gates Foundation
This is a pragmatic, open-label, randomised control trial of three oral anti-hypertensive regimens for women with severe hypertension in pregnancy. Women presenting with severe hypertension in pregnancy in two hospitals in Nagpur, India will be randomised to one of three oral regimens: nifedipine, labetalol or methyldopa. This trial will compare the efficacy, safety and side effects of these three oral regimens for management of hypertension in pregnant women. The investigators hypothesize that nifedipine treatment of severe hypertensive parturient women is more effective than treatment with labetalol or methyldopa in controlling high blood pressure within six hours.
Age
18–50
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Pregnant gestational age \>= 28 weeks
Systolic blood pressure \>=160 mm Hg OR a diastolic blood pressure of \>=110 mm Hg measured twice more than 15 minutes apart
Able to swallow pills
\>= 18 years
You may not be if
Indication for emergent cesarean or known fetal anomaly
Anti-hypertensive therapy received in the past 12 hours
History of eclampsia or other adverse CNS complication (e.g., stroke or PRES) in this pregnancy
Actively wheezing at time of enrollment or history of asthma complications
Known coronary artery disease or type I DM with microvascular complications or signs of heart failure or clinical dissection of the aorta